MYC and prostate carcinoma: Moreover, in prostate cancer, the observed downregulation of miR-27a-5p, due to promoter methylation and c-MYC aberrant activation [31], has been proposed as a mechanism that may lead to increased levels of TOP2A, MELK, and CENPF, which represent predicted miR-27a-5p targets associated to poor prognosis [36,37] and development of metastases [38].